AA
ALNY icon

Ancora Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Ancora Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.31K Hold
11
– – ﹤0.01% 1695
2026
Q1 		$3.64K Sell
11
-11
-50% -$3.74K ﹤0.01% 2040
2025
Q4 		$8.75K Buy
+22
New +$9.74K ﹤0.01% 1828
2023
Q1 		– Sell
-2
Closed – – 1955
2022
Q4 		$0 Buy
+2
New +$427 ﹤0.01% 1792

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ancora Advisors's ALNY Position: Q2 2026 in Review

Ancora Advisors held its Alnylam Pharmaceuticals (ALNY) position steady in Q2 2026 at 11 shares worth $3.31K. The position accounts for ﹤0.01% of the portfolio, ranked #1695.

Ancora Advisors first reported a position in ALNY in Q4 2022 and has held it in 4 quarters since. The position peaked at $8.75K in Q4 2025. 793 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Ancora Advisors held 11 shares of Alnylam Pharmaceuticals worth $3.31K as of Q2 2026.
  • Ancora Advisors left its Alnylam Pharmaceuticals share count unchanged in Q2 2026.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Ancora Advisors's portfolio in Q2 2026, its #1695 holding.
  • Ancora Advisors first reported a position in Alnylam Pharmaceuticals in Q4 2022 and has held it in 4 quarters since.
  • Ancora Advisors's Alnylam Pharmaceuticals position peaked at $8.75K in Q4 2025.
  • 793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Ancora Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.